🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
26.58
-0.64 (-2.35%)
At close: Nov 20, 2026, 4:00 PM EST
26.76
+0.18 (0.68%)
After-hours: Nov 20, 2026, 7:59 PM EST
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 16, 2026

Summary

TRYNGOLZA’s early launch is progressing as HCPs gain experience, with label-wide payer coverage and a $3B+ U.S. peak-sales outlook. Pipeline milestones include ION775 Phase III planning in 2027 and Angelman syndrome data expected in H2 2027.

Operator

All right, we'll get started. Thank you for joining us this morning for inaugural UBS Global Biopharma Conference. For this session, we have Dr. Brett Monia, CEO of Ionis. Brett, thanks for joining us for this fireside chat. For the audience who may be new to the story, could you just spend a few minutes describing who Ionis is, your recent accomplishments, and why investors should pay attention to Ionis now?

Brett Monia
CEO, Ionis Pharmaceuticals

Sure. Thanks, Joon. It's great to be here. So, yeah, so for those that aren't that familiar with Ionis is a pioneer in oligonucleotide therapeutics targeting RNA. You may be familiar with antisense technology, siRNA technology. That's really where we're focused, and we're the leaders in this space. Today, we have seven FDA-approved medicines for eight disease indications. That's the most of any oligonucleotide company that's out there today. About half of those approved medicines we're commercializing ourselves in the United States, and then the other half, we have pharma partners that are commercializing or developing. In addition, we have a very rich phase III late-stage pipeline at Ionis. Just recently, in the last few months, we announced positive phase III data for two programs, one in kidney disease and another in a genetic form of ALS.

We have four phase III programs in development today, and more expecting next year. Some are wholly owned, as well as some are our partner. We have a rich mid-stage pipeline. Basically, we have a technology, a platform, and a pipeline that's positioned to deliver a steady cadence of breakthrough treatments for common diseases as well as rare genetic diseases we've already done, as well as in the near future, as well as in a long-term basis. Ionis is very well-positioned to continue to deliver breakthrough medicines for many years to come.

Operator

Thank you for that. Let's start with your lead drug, the most important drug at the moment, TRYNGOLZA, recently approved for severe hypertriglyceridemia. It's a large opportunity. The launch has been slower than expected, as you admitted on the call. What gives you confidence that TRYNGOLZA can actually achieve $3+ billion in sales, and how do you get there?

Brett Monia
CEO, Ionis Pharmaceuticals

TRYNGOLZA is a breakthrough for a condition called severe hypertriglyceridemia. This is a lipid. Triglycerides are a lipid in this population in which triglycerides are 10x, 20x, sometimes 50 x higher than normal levels of triglycerides. These patients suffer from a whole range of comorbidities, but most importantly, the risk of a potentially fatal acute pancreatitis attack of the pancreas. If it's not fatal, it's highly debilitating and is recurring, so eventually it can lead to pancreatic failure and organ failure and so on. Prior to TRYNGOLZA, there have been no effective treatments for severe hypertriglyceridemia. What we showed in our phase III trial was that not only can we normalize many patients' triglycerides who have severe hypertriglyceridemia, but we can actually reduce the incidence of acute pancreatitis attacks, so outcome data, if you will. That's never been shown before.

We were first to do it, and we're the only FDA-approved medicine that can do this. We're talking millions of people in the U.S. alone, equal in Europe, that have severe hypertriglyceridemia. About 1 million of those several million are what we consider to be high risk. They've already had acute pancreatitis attacks, or their triglycerides are so high that they're going to have one eventually, probably. TRYNGOLZA is positioned to be able to deliver. That is a big part of the confidence, is the incredible profile that we delivered in our phase III trial, reductions in acute pancreatitis and triglycerides, while good safety, tolerability, and the convenience of once-per-month self-administration using an auto-injector. A compelling profile and the very, very high unmet medical need. You mentioned that the launch is off to a slower start than expected.

Let's keep in mind that we're only three months into a launch in which we're creating a brand new category, like a brand new therapeutic area where HCPs need to get familiar with the first time a treatment's available to treat this disease, this condition that they've been managing for a long time. They have to get familiar with the process. They have to get familiar with a very novel mechanism of action. There are conditions that are required to prescribe TRYNGOLZA. You have to get a triglyceride measurement and prove that you have severe hypertriglyceridemia. You have to have at least tried another triglyceride-lowering drug, a generic drug, like a fibrate or so on, and they have to get familiar with the office process and that kind of thing.

We remain confident, despite a slightly slower ramp than what we originally expected in the multi-billion dollar product opportunity that TRYNGOLZA offers.

Operator

This acute pancreatitis, people sometimes view severe hypertriglyceridemia as yet another lipid disorder, but it causes AP. Can you contextualize that for the investors, the severity of that, and what could happen if you have that?

Brett Monia
CEO, Ionis Pharmaceuticals

It can be fatal, and oftentimes is fatal. It is the number one cause of acute pancreatitis fatality of any cause. You can get acute pancreatitis from alcoholism or from other conditions, diabetes, but the number one cause of fatality due to acute pancreatitis is severely elevated triglycerides. If it is not fatal, almost all the time it lands an individual in an ICU, an intensive care unit, in which they have to stay in an intensive care unit up to a week or two before they can get out of that unit and then go on. Then they are at risk for another attack down the road if they cannot get their triglycerides down. The other thing about acute pancreatitis is that there is almost nothing that a physician can do when they are in the ICU, right?

They feed them intravenous fluids and they give them pain medications, but there is nothing that they can do to prevent the acute pancreatitis, to reverse that condition. So, the unmet need is very high. It is a severe outcome. Before TRYNGOLZA, there really have been no prophylactic approaches that can prevent that from happening.

Operator

What is it that the prescribers are waiting for? What are they looking for? Given this, and every KOL we spoke with, the data looks really great. You reduce acute pancreatitis risk by 80%, 90%—

Brett Monia
CEO, Ionis Pharmaceuticals

Right

Operator

—ish. What exactly are they waiting for?

Brett Monia
CEO, Ionis Pharmaceuticals

Few things. One is familiarity. Familiarity with a brand new medicine, a new class of medicine, a new mechanism of action. We were the first to validate this mechanism of action for triglyceride lowering, targeting a lipoprotein that is called apoC-III. They want to get familiar with that, they want to get familiar with the medicine, they want to get familiar with the process that qualifies a patient. As I mentioned before, a generic triglyceride-lowering drug will have to fail. Most of these patients, many of these patients are on those drug treatments already anyway. They have to get a measure, a triglyceride measure. They want to make sure the office process is not too cumbersome. We target cardiologists, endocrinologists, lipid specialists.

A lot of cardiologists have had bad experiences with other meds that have caused processes in their offices to really get backed up because the access has been very difficult. We are streamlining that, but they want to get familiar with that. They also want to see that sometimes the clinical outcome. One of the things that we are seeing is a lot of enthusiasm, HCP to prescribe TRYNGOLZA.

Many of the physicians that are the early adopters for TRYNGOLZA want to see that first patient experience. They want to see the process be smooth, access, and they want to see those triglycerides plummet. Of about more than 1,500 HCPs that have prescribed TRYNGOLZA since the first few months of the launch, 75% of them have only prescribed one patient.

Despite the fact that they are managing dozens and dozens and dozens of these patients. They want to get that experience. We are seeing multiple prescriptions being written by HCP growing as they get that experience and they are seeing triglycerides plummet. A lot of that is familiarity with it. The other thing is cardiologists tend to prioritize LDL cholesterol. They are familiar with that, and then they get the triglycerides.

Operator

Yeah.

Brett Monia
CEO, Ionis Pharmaceuticals

Endocrinologists like to focus on the diabetes, get that under control, then focus on the triglycerides. There is also that kind of step-through prioritization process that HCPs are going through. The feedback has been very positive. As you mentioned, the enthusiasm of HCPs is very high. It is just going to take a little bit of time to reach the peak opportunity that TRYNGOLZA offers.

Operator

Based on the recent conference call from Arrowhead, it is pretty clear that they are also talking to payers. How is Arrowhead talking to payers ahead of approval and without a label impacting your ability to get access from payers as well?

Brett Monia
CEO, Ionis Pharmaceuticals

I cannot speak for competition, but I could tell you that we spent a lot of time talking to payers before we had our phase III data.

Operator

Yeah.

Brett Monia
CEO, Ionis Pharmaceuticals

Once we had our phase III data, before we got approval. I forgot to mention earlier that TRYNGOLZA for severe hypertriglyceridemia is its second indication that it is approved for. The first indication was familial chylomicronemia syndrome, which is severe hypertriglyceridemia due to a genetic cause of that disease. sHTG, severe hypertriglyceridemia, is not a known genetic cause. FCS is a rare form of the disease. Our price for that was a rare disease price. Based on all the payer research we did prior to us even having approval, we were engaging with payers to set the price such that when we went from a rare to a common disease, we had the right price to maximize access. Payers would support the full label for the drug and so on. It is not uncommon to have those payer discussions prior to getting approval.

The most productive discussions are after you have your phase III data and you are really getting approval. It is not uncommon to do that.

Operator

To facilitate your commercial uptake, you have this thing called Quick Start program. Tell us a little bit about that program, how many patients, or qualitatively, are participating in that, and how you expect that to facilitate uptake—

Brett Monia
CEO, Ionis Pharmaceuticals

Yeah

Operator

in the next—

Brett Monia
CEO, Ionis Pharmaceuticals

It's very important. One of the most important things for a physician to experience coming into a new drug, a new mechanism of action, is to get their patients onto that drug as quickly as possible. They don't want to write a prescription and then ask three months later, "Why is my patient on the drug?" Because of medical exception or the processes you have to go through in an early launch, sometimes to get payer access and that kind of thing. A Quick Start program allows us to get patients on drug as quickly as possible. That's important for the reason I just said, for a physician to say, "Okay, great. My patient's on the drug." But also to get that positive experience that TRYNGOLZA's delivering. We're seeing triglycerides plummet soon after getting onto TRYNGOLZA, within a month or so.

The access in the office is going very smoothly. Once they get that experience, an HCP is going to be inclined, and that's what we're seeing, to prescribe more. The Quick Start program is absolutely very important because we want to garner that really positive experience that TRYNGOLZA is delivering.

Operator

PCSK9s have been impressive data in lowering LDL, but took a while to take off and get commercial traction. Do you expect sHTG to be as gradual or faster?

Brett Monia
CEO, Ionis Pharmaceuticals

Oh, it's hard to predict launches in a new area. I think they're very different. PCSK9s, when they first launched, did not have outcome data.

Operator

Yeah.

Brett Monia
CEO, Ionis Pharmaceuticals

They got that eventually. They also probably got the pricing wrong out of the gate, which caused payers to push back on access. We have not experienced either of those. First of all, we have outcome data. We have acute pancreatitis data. That's our outcome data.

Operator

Yeah.

Brett Monia
CEO, Ionis Pharmaceuticals

It's very strong and highly statistically significant, and it's in the indication statement. Second, our payer research that I referred to earlier has been very well received by the payer community. We dropped the price to maximize access, to maximize value. So far, payers are covering TRYNGOLZA to label. They're not requiring extensive hurdles to overcome to cover commercial product. They're not restricting the label to a subset of patients that are at the highest risk, for example, for acute pancreatitis. They're covering to label, which is patients with triglycerides 500mg per deciliter and above, regardless of history of acute pancreatitis. I think they're different. We don't really have a good analog for launch that we've been able to settle on that we're comfortable with yet. We don't think PCSK9s are a good analog.

Operator

Great. At any rate, you reiterated $3+ billion in peak sales. That was a relief to hear. But you have competition. Arrowhead is expecting to have their REDEMPLO approved in 2Q 2027 for sHTG as well, and they're also saying their drug is going to be $3 billion- $4 billion in peak sales. Can both drugs achieve their stated peak sales, you $3+ billion and Arrowhead's drug $3+ billion-$4+ billion ? Or does your drug achieving, does TRYNGOLZA achieving $3+ billion require Arrowhead to do less, or how does that work?

Brett Monia
CEO, Ionis Pharmaceuticals

Our assumption is that we'll have a competitor that has a profile similar to ours once they get to the market. We're ahead about a year and a half. But our assumption of $3+ billion peak sales, as well as theirs, is what I've heard, assumes that there's two players in the market and both are doing that well once we get to peak sales. It's not necessarily a negative outcome to have two players in a brand new nascent market that's treating millions of people, right? It actually helps to have a couple of players in there that are educating on the need to First of all, what is severe hypertriglyceridemia? What is the risk of sHTG? How do we educate HCPs on the need and the urgency to treat, and the patients, patient awareness of disease as well?

Actually, having two players in this market will actually increase the share of voice and could potentially benefit everybody.

Operator

I agree. I mean, in medical school, I've seen acute pancreatitis. It's not pleasant to watch.

Brett Monia
CEO, Ionis Pharmaceuticals

Yeah.

Operator

It's not pleasant to have a patient go through that. So I do think it's a medical emergency. In fact, we really had to go low on the penetration to get our peak sales for TRYNGOLZA. I mean, what's the upside actually? I just think $3 billion is very conservative, but why $3 billion? Because there are 1 million high risk and 3 million who might actually, who, to your label, qualify. So, are you being overly conservative here, or what is your estimate based on?

Brett Monia
CEO, Ionis Pharmaceuticals

Yeah. There's always upside. We have said $3+ billion . There's always the potential upside. Let's get there. That is a U.S. market peak sales, by the way. We also have a partner for OUS commercialization in Sobi. We have a positive CHMP opinion, and we expect approval by the end of this year in Europe or early next year. Our partner, Sobi, has estimated north of $1 billion for Europe for sHTG. So it is a bit more than $3+ billion . That is referring to the U.S. market. There's always the potential for upside, but again, we're creating a new market, and we're sticking with the $3+ billion at this point.

Operator

Yeah. You are doubling down on this space. You have already a lifecycle management program.

Brett Monia
CEO, Ionis Pharmaceuticals

Yeah

Operator

In, what is it? Ionis, ION775. It is a siRNA program. What are you trying to solve with 775 that you cannot solve with TRYNGOLZA?

Brett Monia
CEO, Ionis Pharmaceuticals

It is not so much we are solving an issue with TRYNGOLZA. TRYNGOLZA has a remarkable profile with efficacy that is unmatched, convenience as a monthly self-administered treatment using an auto-injector, excellent tolerability and safety. Really, our follow-on molecule is an approach to further enhance convenience. Based on our phase I data, we are now in phase II in sHTG, with plans to maybe start the process to get to phase III next year. It is really convenience. This molecule has the potential to be once per year self-administration, or at a maximum, twice per year administration. So it is really a convenience play. It is going to be tough to beat the profile, the efficacy profile for TRYNGOLZA.

It has the potential to do so. We may get deeper reductions in triglycerides. But really, it is to make it even more convenient for patients as a once or twice a year administration.

Operator

We did quite a few doc calls before we initiated coverage of you and Arrowhead as well, and we asked a lot of endocrinologists and cardiologists and lipidologists, and bottom line, their conclusion is that we will just use whatever we have access to. So, what is going to determine a payer to reimburse this versus that, and what is the conversation?

Brett Monia
CEO, Ionis Pharmaceuticals

I think you said it. What we believe will be a key component to preferential prescription making, or prescription writing, will be how easy it is to get patients onto drug, how quickly they get them onto drug, access, right? Is how much of a hassle is it to get coverage, to get the patient converted over to drug after you write the prescription? The other key aspect of TRYNGOLZA, of course, is we're first to market. We're targeting those patients with the highest risk. Those are patients with a history of acute pancreatitis or the triglycerides are so high, the likelihood of an acute pancreatitis attack is very high. We have the ability to get to those patients first and lock those up. What we know is once patients get on and HCPs experience TRYNGOLZA, the experience is very positive, and they're staying on treatment.

Operator

Yeah.

Brett Monia
CEO, Ionis Pharmaceuticals

Because they're seeing triglycerides plummet with really good tolerability. I think one of the most important things for physicians to do, to experience, is an easy access to the drug.

Operator

It's not a rare disease by any means. It's a large indication. For a large indication like this, does it make sense to do some more direct-to-consumer, omnichannel, more focused advertisement so that they actually ask their doctors about it? Any thoughts there to increase awareness and help with the uptake?

Brett Monia
CEO, Ionis Pharmaceuticals

Yeah. Patient education is definitely a key aspect of the launch and the success of TRYNGOLZA that we're focusing on. HCP education, patient education, know your triglycerides, know the risks of high triglycerides, and eventually be aware that now there are effective treatments out there to manage your triglycerides. We're using several approaches to reach patients.

Operator

Yeah.

Brett Monia
CEO, Ionis Pharmaceuticals

Most importantly is digital, omnichannel approaches, right? We're providing knowledge or experiences, education around what your triglycerides are, what's the risk of high triglycerides, and so on. We can reach many, many patients and HCPs through omnichannel that you would never be able to reach with just boots on the ground. That is direct to consumer.

Operator

Yeah. I do think having two voices in this space and targeting the same target validates the target, and that would help. I think it's a bit of a rising tide raises all boats situation. You have another drug that recently launched, ZANVASTRO, for Alexander disease. Tell us a little bit about that and how that launch is going.

Brett Monia
CEO, Ionis Pharmaceuticals

Yeah. Unlike sHTG, which is millions of people, ZANVASTRO is an ultra-rare disease. It's a neurodegenerative disease called Alexander disease. It's genetic. It's typically fatal. Newborns are born, and then after a year or two, they're not hitting their development milestones, and the diagnosis comes that their child's probably going to perish due to this disease. We are targeting the root cause of Alexander disease, the overproduction of a protein, a myelin protein called GFAP, which we're normalizing, lowering it. We showed for the first time a disease-modifying benefit, so halting the disease progression in our phase III trial of ZANVASTRO for Alexander disease. That's incredibly important for this patient community. We have guided to peak U.S. sales of north of $100 million. So it's not TRYNGOLZA, which is multi-billion, but it's really important for the community, and it's also significant for Ionis from a revenue standpoint.

More importantly, we have a longstanding role as leaders in neurodegenerative, developing novel therapies for neurodegenerative and neurodevelopmental diseases, right? This is the third FDA-approved neurology drug that came from Ionis. SPINRAZA, the first ever approved medicine for spinal muscular atrophy. QALSODY, the first ever approved medicine for a genetic form of ALS. And now ZANVASTRO for Alexander disease. ZANVASTRO is our first independent launch. We partnered QALSODY, we partnered SPINRAZA. This is our first independent launch. Right on the heels of ZANVASTRO is a pipeline of wholly owned neurology drugs that we're developing, including our phase III program in Angelman syndrome, which is a rare disease, but there's about 100,000 people with Angelman syndrome, a neurodevelopmental disease that is in phase III development, where we expect to have phase III data in the second half of next year.

It is strategic for Ionis in that it is our first independent launch in neurology, especially since we have such a rich pipeline.

Operator

I think you are doing the right thing by taking charge of your own destiny by launching your own drugs, and you stole my thunder on obudanersen because that is a very important pipeline drug for you. As you said, huge TAM, high unmet need, and I go to ASF and FAST, and there is a lot of interest in your drug. As you know, recently there was a little bit of a disappointment, actually a huge disappointment from GTX-102. Why is that not a way through to obudanersen ?

Brett Monia
CEO, Ionis Pharmaceuticals

Angelman syndrome is an incredible destructive disease, not just for the individuals that have it, but for families. It is such a huge burden on families in the HCP community and the healthcare community. These individuals usually do not progress past an intellectual capability of a few years of age, like five or six years of age, but yet they have normal lifespan. So you can imagine what a burden that is on families. There are no effective treatments, and it is a very tight community, like you said, Joon. They are very, very tight. The data by the competitor program that failed was unfortunate for that community. However, we were not surprised by the outcome because we had been saying for quite some time that we believe that they were vastly, grossly underdosing.

They were using a much lower dose than what we are using, about five, six-fold lower dose than what we are using in our phase III trial, despite the fact that the two drugs are equal potent. They were dose capped by regulators because they ran into toxicity issues that prevented them being allowed to go to higher doses, what we think would be in the efficacious range. We are at the efficacious range based on our phase II open-label data and other data. I also want to come back to the fact that we have a long history of neurological diseases with three approved medicines, other proof of concepts that have already been achieved in neurology and so on. So we know how to do neurology drug development. We have delivered on these types of products, but we think we are at the right dose.

Operator

But there are certainly differences in the doses that you're giving, much higher. Then fortunately, you haven't run into this weird lower limit, lower extremity AEs. Having said that, are there biomarkers that can point to that helps you, that tell us that you're actually engaging your target thoroughly, or?

Brett Monia
CEO, Ionis Pharmaceuticals

Yeah. There's a lot of work being done to measure the protein. So what we're doing, this is a loss of function disease in which our mechanism is very novel. It actually is increasing the production of the protein that is lacking that causes this disease. But unfortunately, assays to measure that protein have been very difficult. Preclinically, we can see an increase in protein production, but you got to do that histologically, like in brain slices. But you can't measure the protein in the circulation. We're working on it, but so far it's not been effective. But we do have another biomarker, which we've shown consistent benefit on. These individuals have abnormal EKG patterns, so their brain electrical circuits are not right.

And what we have shown, that by targeting with obudanersen in individuals with Angelman syndrome, is that we can normalize a lot of these EEG patterns, EKG patterns, for in patients. And that's kind of like a biomarker because it precedes the benefit that we're seeing clinically. But we're still working on a protein assay.

Operator

You mean EEG?

Brett Monia
CEO, Ionis Pharmaceuticals

EEG.

Operator

Yeah, exactly.

Brett Monia
CEO, Ionis Pharmaceuticals

Sorry.

Operator

You do not have any febrile AEs or things of that nature?

Brett Monia
CEO, Ionis Pharmaceuticals

No. It has been very well tolerated. We have not had lower limb extremity issues or radiculopathies or those types of things. The drug has been very well tolerated. As I mentioned before, we set out to go to a maximum dose of 80mg quarterly, and we achieved that with good safety.

Operator

Yeah. No, it is reassuring that your platform had generated other CNS drugs and they have been successful. We have a minute left. Anything you want to say before we observe the fireside chat?

Brett Monia
CEO, Ionis Pharmaceuticals

Ionis is a growth story. I mean, we have a pipeline that's second to none, late stage, mid-stage. We have product approvals, launches are underway, partner launches, our own launches. I mean, we're in a position to create tremendous value in a consistent and well into the future, near term as well into the future, by delivering a steady cadence of breakthrough treatments over and over again. It's exciting times.

Operator

All right. With that, I think we're out of time. Thank you so much for your attention, and thank you, Brett.

Brett Monia
CEO, Ionis Pharmaceuticals

Thank you.

Operator

Thank you.